Skip to main content
Premium Trial:

Request an Annual Quote

FDA to Use Ariana for Genomic Data Tools

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ariana Pharma will provide its biomarker data mining technology to the US Food and Drug Administration for its efforts to develop better tools for analyzing genomic data to be used in personalized medicine.

Under a collaborative agreement, FDA will use Ariana's KEM Biomarker technology to analyze data combined with patient characteristics for biomarker signatures that were submitted to FDA through its Voluntary Exploratory Data Submission program, the Paris-based company said today.

"We are looking forward to this collaboration to help the agency systematically analyze all equivalent signatures combining both genomic and phenotypical data," Federico Goodsaid, associate director for operations in genomics in the Office of Clinical Pharmacology at the Center for Drug Evaluation and Research at the FDA, said in a statement.

Ariana Pharma's KEM platform mines and extracts data and enables researchers to make decisions that involve multiple criteria and objectives, the company said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.